Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]
It has been announced by the International Strategic Cancer Alliance that a Dutch university that intends to launch global trials has purchased the Combidex technology. Combidex is a scan contrast that periodically gets discussed among prostate cancer survivors, but it has not been available for a few years. It is an injectable nanoparticle fluid (contrast) [...]
The commonly used serum (blood) marker for inflammation is C-reactive protein (CRP). It is believed that CRP has a prognostic impact for men with metastatic prostate cancer (MPC) (advanced prostate cancer). The researchers conducted a meta-analysis to quantitate its prognostic impact. They conducted asystematic review to identify publications and presentations exploring the association of baseline [...]
The best way to understand your PSA kinetics, especially its changes, is to be able to visualize them on a graph. This allows you to understand significant changes in our PSA earlier on than you might otherwise perceive them. Any man whether diagnosed with prostate cancer or not should be recording their PSA scores and [...]
As I have said before, the true unsung heroes of our fight against advanced prostate cancer are our caretakers. Our caretakers are our saints, they help educate us, they advocate for us, they shield us and they make us as complete as we can possibly be. They improve our lives and help us get through [...]
An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and count these cells in the blood) are prognostic for most men with metastatic prostate cancer (mPC), but are not well [...]
Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT). [...]
Live in the UK and have advanced prostate cancer? If you do then be prepared to have economics over-ride your legitimate health concerns. The U.K.'s National Institute for Health and Care Excellence (NICE) makes no bones about what is more important, money or men’s health. NICE initially did not approve Zytiga, however when Johnson & [...]
A John’s Hopkins Health Alert titled “How Long Is It Safe to Take Bisphosphonates for Osteoporosis?” Should Raise Some Concerns Men on Long Term Bisphosphonate Therapy Hormone therapy (ADT) is notorious for many negative side effects, including osteoporosis. Osteoporosis is the thinning of bone that increases the risk for fractures, especially hip and spine fractures. [...]
In response to the post I wrote about Choline C-11 on December 11, 2013 Choline C-11 A Second Shot To Halt the Cancer After Primary Treatment Failure one of our group members contact me and shared that he was scheduled to have a similar scan. I asked if he would be willing to share his [...]
